IN2012DN02826A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02826A IN2012DN02826A IN2826DEN2012A IN2012DN02826A IN 2012DN02826 A IN2012DN02826 A IN 2012DN02826A IN 2826DEN2012 A IN2826DEN2012 A IN 2826DEN2012A IN 2012DN02826 A IN2012DN02826 A IN 2012DN02826A
- Authority
- IN
- India
- Prior art keywords
- day
- weeks
- amount
- toxin
- infusion
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000001802 infusion Methods 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002596 immunotoxin Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention relates to a method of treatment and dosing regimen for treating disease, such as cancer and mammalian tumors, wherein therapy with a cytotoxic drug is suitable, by the administration of an antibody-toxin conjugate, such as a maytansinoid toxin, by infusion at an initial infusion rate of 1 mg/min or lower on a schedule selected from the group consisting of: (1) an amount of at least about 90 mg/m2 on day 1 and day 8, every three weeks; (2) at least an amount of about 30 mg/m2 on day 1, day 2 and day 3, every three weeks; (3) at least an amount of about 45 mg/m2 on day 1, day 8, and day 15, every 4 weeks; and (4) at least an amount of about 45 mg/m2 on day 1, day 8 and day 15, every 3 weeks.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25380409P | 2009-10-21 | 2009-10-21 | |
| PCT/US2010/053579 WO2011050180A1 (en) | 2009-10-21 | 2010-10-21 | Novel dosing regimen and method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02826A true IN2012DN02826A (en) | 2015-07-24 |
Family
ID=43898626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2826DEN2012 IN2012DN02826A (en) | 2009-10-21 | 2010-10-21 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110097345A1 (en) |
| EP (1) | EP2490715A4 (en) |
| JP (1) | JP2013508400A (en) |
| KR (1) | KR20120094472A (en) |
| CN (1) | CN102630165A (en) |
| AU (1) | AU2010310577A1 (en) |
| BR (1) | BR112012009250A2 (en) |
| CA (1) | CA2775806A1 (en) |
| IL (1) | IL219279A0 (en) |
| IN (1) | IN2012DN02826A (en) |
| MX (1) | MX2012004406A (en) |
| RU (1) | RU2012120691A (en) |
| WO (1) | WO2011050180A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| US20110177064A1 (en) * | 2010-01-21 | 2011-07-21 | Immunogen, Inc. | Compositions and Methods for Treatment of Ovarian Cancer |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| WO2014018563A2 (en) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for the treatment of cancer |
| WO2014052876A1 (en) * | 2012-09-28 | 2014-04-03 | Immunogen Inc. | Methods for increasing efficacy of cd56- based therapy |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| KR20240068778A (en) * | 2013-05-14 | 2024-05-17 | 이뮤노젠 아이엔씨 | Anti-folr1 immunoconjugate dosing regimens |
| MX384973B (en) * | 2013-10-08 | 2025-03-14 | Immunogen Inc | ANTI-FOLATE RECEPTOR 1 (FOLR1) IMMUNOCONJUGATE DOSING REGIMEN. |
| AU2015204766B2 (en) * | 2014-01-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| CA2954934C (en) | 2014-06-30 | 2023-09-26 | Glykos Finland Oy | Drug derivative and conjugates |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| JP6998938B2 (en) * | 2016-08-10 | 2022-02-04 | セルジーン クオンティセル リサーチ，インク． | Treatment of recurrent and / or refractory solid tumors and non-Hodgkin's lymphoma |
| BR112019010131A2 (en) | 2016-11-21 | 2019-10-08 | Eirion Therapeutics Inc | transdermal delivery of large agents |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| SG11202012257VA (en) * | 2018-06-26 | 2021-01-28 | Immunogen Inc | Immunoconjugates targeting adam9 and methods of use thereof |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| WO2021245233A1 (en) * | 2020-06-04 | 2021-12-09 | Bioinvent International Ab | Improving antibody tolerabilty associated with intravenous administration |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| WO2024230793A1 (en) * | 2023-05-10 | 2024-11-14 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors and methods of use thereof |
| CN120173115A (en) * | 2025-05-20 | 2025-06-20 | 苏州欣协生物科技有限公司 | An anti-human CD56 protein engineering antibody and its preparation method |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US7303749B1 (en) * | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| EP2289549A3 (en) * | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| WO2003024388A2 (en) * | 2001-09-20 | 2003-03-27 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for psma |
| US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| JP4703566B2 (en) * | 2003-05-14 | 2011-06-15 | イムノゲン インコーポレーティッド | Drug complex composition |
| US20060281813A1 (en) * | 2003-06-05 | 2006-12-14 | Charles Rubin | Methods of treating hyperproliferative cell disorders |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| ZA200708694B (en) * | 2005-04-15 | 2009-01-28 | Immunogen Inc | Elimination of heterogeneous or mixed cell population in tumors |
| EP3753576A1 (en) * | 2006-09-26 | 2020-12-23 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| BRPI0914789A2 (en) * | 2008-06-16 | 2015-10-20 | Immunogen Inc | synergistic effects |
| US20110177064A1 (en) * | 2010-01-21 | 2011-07-21 | Immunogen, Inc. | Compositions and Methods for Treatment of Ovarian Cancer |
| AU2012240448A1 (en) * | 2011-04-01 | 2013-03-28 | Immunogen, Inc. | Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer |
-
2010
- 2010-10-21 BR BR112012009250A patent/BR112012009250A2/en not_active IP Right Cessation
- 2010-10-21 RU RU2012120691/15A patent/RU2012120691A/en unknown
- 2010-10-21 CA CA2775806A patent/CA2775806A1/en not_active Abandoned
- 2010-10-21 JP JP2012535373A patent/JP2013508400A/en not_active Withdrawn
- 2010-10-21 AU AU2010310577A patent/AU2010310577A1/en not_active Abandoned
- 2010-10-21 MX MX2012004406A patent/MX2012004406A/en not_active Application Discontinuation
- 2010-10-21 CN CN2010800455971A patent/CN102630165A/en active Pending
- 2010-10-21 EP EP10825683.5A patent/EP2490715A4/en not_active Withdrawn
- 2010-10-21 WO PCT/US2010/053579 patent/WO2011050180A1/en active Application Filing
- 2010-10-21 US US12/909,697 patent/US20110097345A1/en not_active Abandoned
- 2010-10-21 KR KR1020127008847A patent/KR20120094472A/en not_active Withdrawn
- 2010-10-21 IN IN2826DEN2012 patent/IN2012DN02826A/en unknown
-
2012
- 2012-04-19 IL IL219279A patent/IL219279A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2490715A4 (en) | 2013-06-26 |
| BR112012009250A2 (en) | 2017-06-20 |
| CA2775806A1 (en) | 2011-04-28 |
| EP2490715A1 (en) | 2012-08-29 |
| MX2012004406A (en) | 2012-05-08 |
| RU2012120691A (en) | 2013-11-27 |
| JP2013508400A (en) | 2013-03-07 |
| US20110097345A1 (en) | 2011-04-28 |
| KR20120094472A (en) | 2012-08-24 |
| CN102630165A (en) | 2012-08-08 |
| IL219279A0 (en) | 2012-06-28 |
| AU2010310577A1 (en) | 2012-04-19 |
| WO2011050180A1 (en) | 2011-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02826A (en) | ||
| MX2022002592A (en) | Antibody-drug conjugate comprising antibody against human ror1, and use for the same. | |
| MX2024000612A (en) | Immunoconjugates and methods. | |
| NZ625391A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| MY151449A (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| EA201500019A1 (en) | METHOD OF TREATMENT OF GD2-POSITIVE CANCER | |
| MY187652A (en) | Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate | |
| EA033400B1 (en) | Anti-cd3 antibody and use thereof | |
| PH12012502373A1 (en) | Aminopyrimidine derivatives as lrrk2 modulators | |
| NZ596807A (en) | Uses of immunoconjugates targeting cd138 | |
| RU2011142281A (en) | ANTIBODIES TO HER | |
| NZ604056A (en) | Novel anti-cmet antibody | |
| NZ603717A (en) | Suture line administration technique using botulinum toxins | |
| NZ588913A (en) | Liver cancer drug | |
| MX2016011333A (en) | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine. | |
| GB0718878D0 (en) | Photodynamic Theraphy and diagnosis | |
| AU2012253610A8 (en) | Compositions and methods for treating cancer | |
| WO2013052158A3 (en) | Targeted nanovectors and their use for treatment of brain tumors | |
| MX2012005497A (en) | Tivozanib and temsirolimus in combination. | |
| SG195192A1 (en) | Non-peptidyl polymer-insulin multimer and method for producing the same | |
| GB201100804D0 (en) | Drug combination | |
| MX2009004247A (en) | Isolated hydroxy and n-oxide metabolites and derivatives of o-desmethylvenlafaxine and methods of treatment. | |
| NZ775405B2 (en) | Humanized antibodies against c-kit | |
| UA33293U (en) | Method for treating chronic endometritis | |
| UA95522C2 (en) | method for treatment of patients with malignant brain tumors with antitumor vaccine |